Sickle cell disease is the most common single-gene disease in the world. Its prevalence is increasing in France, with patients' life expectancy increasing into developed countries. It mainly affects populations originating from sub-Saharan Africa. Among the chronic bone complications associated with sickle cell disease, osteoporosis has previously been highlighted but remains a poorly known complication in this very particular context. A dedicated evaluation of osteoporosis and associated risk factors in sickle cell disease patients living in France may enable better bone management of these patients in the future, as this problem, specific to their disease, is likely to become more frequent as their life expectancy increases.

This is a prospective interventional and monocentric study whose objective is to describe the prevalence of osteoporosis in black patients with sickle cell disease in France

Inclusion Criteria:

• Black-skinned men and women
• Aged 20 to 40 years old
• Sickle cell patients
• Non-opposition to participate in the study

Exclusion Criteria:

• Refusal to participate in the study
• Hemoglobinopathy other than sickle cell disease
• Severe or End Stage Renal Failure
• Long-term corticosteroid therapy (>3 months)
• History of solid cancer or malignant haemopathy
• History of organ transplantation
• Pregnant or breastfeeding woman
• Psychiatric pathology seriously impeding understanding
• Difficulty understanding oral French

sickle cell adult patients hospitalized (conventional or day hospitalization) or followed in consultation in internal medicine within the framework of their sickle cell disease at Edouard Herriot Hospital, Lyon, France